Blueprint Medicines Corporation (BPMC) News

Blueprint Medicines Corporation (BPMC): $100.57

1.79 (-1.75%)

POWR Rating

Component Grades








Add BPMC to Watchlist
Sign Up

Industry: Biotech




#115 of 355

in industry

Filter BPMC News Items

BPMC News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

BPMC News Highlights

  • BPMC's 30 day story count now stands at 10.
  • Over the past 12 days, the trend for BPMC's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
  • The most mentioned tickers in articles about BPMC are ASH, AXSM and GILD.

Latest BPMC News From Around the Web

Below are the latest news stories about BLUEPRINT MEDICINES CORP that investors may wish to consider to help them evaluate BPMC as an investment opportunity.

Blueprint Medicines to Present at 42nd Annual J.P. Morgan Healthcare Conference

Blueprint Medicines Corporation (Nasdaq: BPMC) today announced that Kate Haviland, Chief Executive Officer, will present a corporate overview and 2024 outlook at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024, at 10:30 a.m. PT (1:30 p.m. ET).

Yahoo | December 18, 2023

Blueprint Medicines Corporation's (NASDAQ:BPMC) 38% Price Boost Is Out Of Tune With Revenues

Blueprint Medicines Corporation ( NASDAQ:BPMC ) shares have continued their recent momentum with a 38% gain in the last...

Yahoo | December 18, 2023

Insider Sell: Director Jeffrey Albers Sells 5,000 Shares of Blueprint Medicines Corp (BPMC)

Blueprint Medicines Corp (NASDAQ:BPMC) has recently witnessed a notable insider sell by Director Jeffrey Albers, who disposed of 5,000 shares of the company's stock.

Yahoo | December 14, 2023

Chart Of The Day: Does Blueprint Medicines Have A Blueprint For Success?

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. | December 13, 2023

Blueprint Medicines' AYVAKYT® (avapritinib) Receives European Commission Approval as the First and Only Treatment for Indolent Systemic Mastocytosis

Blueprint Medicines Corporation (Nasdaq: BPMC) today announced the European Commission has approved AYVAKYT® (avapritinib) for the treatment of adult patients with indolent systemic mastocytosis (ISM) with moderate to severe symptoms inadequately controlled on symptomatic treatment. AYVAKYT is the first and only approved therapy for people living with ISM in Europe.

Yahoo | December 12, 2023

Blueprint Medicines' (NASDAQ:BPMC) investors will be pleased with their respectable 63% return over the last year

The simplest way to invest in stocks is to buy exchange traded funds. But you can significantly boost your returns by...

Yahoo | December 11, 2023

12 Best Genomics Stocks To Buy Now

In this piece, we will take a look at the 12 best genomics stocks to buy now. If you want to skip our introduction to the genomics industry and all the latest trends, then take a look at 5 Best Genomics Stocks To Buy Now. If there’s one thing that can be said with certainty […]

Yahoo | December 10, 2023

Blueprint Medicines' Leadership in Driving Continued Innovation in Systemic Mastocytosis Highlighted at 2023 ASH Annual Meeting

Blueprint Medicines Corporation (Nasdaq: BPMC) today announced data showcasing its commitment to advance the scientific understanding and treatment of systemic mastocytosis (SM) at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition being held December 9-12 in San Diego. Data that will be presented include results from the HARBOR Part 1 trial of elenestinib in indolent systemic mastocytosis (ISM) and analyses of real-world data highlighting the burden of and urgency to tr

Yahoo | December 9, 2023

Why Is Gilead (GILD) Up 1.9% Since Last Earnings Report?

Gilead (GILD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Yahoo | December 7, 2023

Why Is Axsome (AXSM) Up 8.7% Since Last Earnings Report?

Axsome (AXSM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Yahoo | December 6, 2023

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!